Reuters was first to report that Indian drug and medical services startup PharmEasy is in talks with investors to raise $200 million, but at a valuation that could be 15% or even 25% lower than last year’s $5.1 billion. Indian startups have been jolted by uncertain global and domestic stock markets and growing investor skepticism over what they say are sky-high valuations, making it difficult for PharmEasy to raise funds at same or a higher valuation.
The post Reuters reveals India’s PharmEasy plans $200 million fundraising at lower valuation appeared first on Reuters News Agency.
Some of the links in this article are "affiliate links", a link with a special tracking code. This means if you click on an affiliate link and purchase the item, we will receive an affiliate commission.
The price of the item is the same whether it is an affiliate link or not. Regardless, we only recommend products or services we believe will add value to our readers.
By using the affiliate links, you are helping support our Website, and we genuinely appreciate your support.